The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
Introduction
The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody (mAb)-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. By analyzing R&D pipelines and the platform technologies in use today, it is possible to better predict where the market will be in the next decade and to envisage which new innovative therapies will become market successes.
Research highlights
The second wave of therapeutic antibody technologies, encompassing optimized full size, fully human antibodies as well as the bits and pieces of individual antibody fragments and alternative binding domains/scaffolds is driving the formation of innovative technology platforms. While biotechs have led the race towards the discovery of novel technologies, big pharma has taken over the reigns for the development of many of these future therapeutic drugs.
In this report, BioSeeker Group has surveyed and categorized the technology platform status of over 100 companies and identified over 150 unique platforms that are shaping the current and future pipeline of monoclonal antibody therapeutics.
Scope of this report:
A single source for market wide competing monoclonal antibody technologies in oncology
Thorough examination of the leading cancer therapeutic antibody technologies
The race towards the next generation of therapeutic antibodies
Competing platforms for expression, delivery, and modification of antibodies
This report will:
improve your competitor analysis
allow you to assess the strengths/weaknesses of competing technologies
outline R&D alignments
allow you to assess the direction of future technologies
